208 related articles for article (PubMed ID: 22691670)
1. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Kwong LM
Orthopedics; 2012 Jun; 35(6):e932-8;discussion e939. PubMed ID: 22691670
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Borris LC
Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
4. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Turpie AG; Lassen MR; Eriksson BI; Gent M; Berkowitz SD; Misselwitz F; Bandel TJ; Homering M; Westermeier T; Kakkar AK
Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
[TBL] [Abstract][Full Text] [Related]
7. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Perzborn E; Kubitza D; Misselwitz F
Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Kwong LM
Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
14. [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Saxer F; Dick W
Z Orthop Unfall; 2010 Jan; 148(1):26-30. PubMed ID: 20135590
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Chen T; Lam S
Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
[TBL] [Abstract][Full Text] [Related]
17. Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.
Imberti D; Prisco D
Pathophysiol Haemost Thromb; 2008; 36(5):217-26. PubMed ID: 19996630
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
19. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
20. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.
Russell RD; Huo MH
J Arthroplasty; 2013 Oct; 28(9):1477-81. PubMed ID: 23540535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
